Edition:
United States

Profile: Endologix Inc (ELGX.O)

ELGX.O on Nasdaq

6.68USD
19 Jul 2019
Change (% chg)

$-0.11 (-1.62%)
Prev Close
$6.79
Open
$6.83
Day's High
$6.83
Day's Low
$6.61
Volume
93,872
Avg. Vol
301,568
52-wk High
$54.00
52-wk Low
$5.20

Endologix, Inc., incorporated on June 2, 1993, is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Sales of the Company's EVAR and EVAS platforms (including extensions and accessories) to hospitals in the United States and Europe, and to third-party international distributors provide the sole source of its revenue. It offers various accessories to facilitate the optimal delivery of its EVAR and EVAS products, including compatible guidewires, snares, and catheter introducer sheaths.

The Company branded its EVAR products under the names, such as Powerlink, IntuiTrak, AFX and VELA. The EVAR products consist of a cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (PTFE) graft material (Stent Graft) and an accompanying delivery system. Once fixed in its proper position within the abdominal aorta, the EVAR device provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for AAA to rupture. Within the Company's EVAR platform, AFX is marketed in the United States, Europe, New Zealand, Japan and Latin America, and Intuitrak sales are limited to Japan.

The Company's EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through blood lumens. The EVAS product consists of bilateral covered stents with endobags, a biocompatible polymer injected into the endobags to seal the aneurysm and a delivery system and polymer dispenser. The EVAS product seals the entire aneurysm sac, excluding the aneurysm sac and reducing the likelihood of future aneurysm rupture. Additionally, it has the potential to reduce the need for post procedural re-interventions. Biostable Polymer provides extended fixation and long-term stability.

The Company competes with Medtronic, Inc., W.L. Gore Inc. and Cook Medical Products, Inc.

Company Address

Endologix Inc

2 Musick
IRVINE   CA   92618-1631
P: +1949.5984741
F: +1949.6999622

Company Web Links